Drug intelligence / Profile preview

Absent in Melanoma 2

Development stage: Preclinical
Lead developer: Biogenea
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Vaccination

Overview

Absent in Melanoma 2 (AIM2) is an interferon-inducible protein that functions as a cytoplasmic sensor for double-stranded DNA (dsDNA), playing a crucial role in innate immunity by forming the AIM2 inflammasome, which triggers inflammatory responses and pyroptosis. In the context of oncology, AIM2 has been identified as a tumor-associated antigen (TAA) expressed in various cancers, including glioblastoma multiforme (GBM). It is utilized as a neoantigenic peptide component within the personalized TAMAVAQ NeoVaccine, developed by Biogenea Pharmaceuticals Ltd., to stimulate tumor-specific T-cell immunity against cancer cells in patients with newly diagnosed glioma.

Other names: Interferon-inducible protein AIM2

Targets

AIM2 (Absent in melanoma 2)

Beyond the preview

Go deeper on Absent in Melanoma 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Absent in Melanoma 2.

Explore the full profile